Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 320

1.

Reduction in HPV16/18 prevalence among young women with high-grade cervical lesions following the Japanese HPV vaccination program.

Matsumoto K, Yaegashi N, Iwata T, Yamamoto K, Aoki Y, Okadome M, Ushijima K, Kamiura S, Takehara K, Horie K, Tasaka N, Sonoda K, Takei Y, Aoki Y, Konnai K, Katabuchi H, Nakamura K, Ishikawa M, Watari H, Yoshida H, Matsumura N, Nakai H, Shigeta S, Takahashi F, Noda K, Yoshikawa H; MINT Study Group.

Cancer Sci. 2019 Oct 9. doi: 10.1111/cas.14212. [Epub ahead of print]

2.

Low antithrombin activity before delivery predicts subsequent hypertensive disorders in pregnancy.

Morikawa M, Umazume T, Nakagawa K, Chiba K, Kawaguchi S, Watari H.

Int J Gynaecol Obstet. 2019 Sep 25. doi: 10.1002/ijgo.12980. [Epub ahead of print]

PMID:
31552678
3.

Pregnancy outcomes in women with rheumatic diseases: a real-world observational study in Japan.

Sugawara E, Kato M, Fujieda Y, Oku K, Bohgaki T, Yasuda S, Umazume T, Morikawa M, Watari H, Atsumi T.

Lupus. 2019 Oct;28(12):1407-1416. doi: 10.1177/0961203319877258. Epub 2019 Sep 24.

PMID:
31551035
4.

Effect of an educational leaflet on the frequency of seat belt use and the rate of motor vehicle accidents during pregnancy in Japan in 2018: a prospective, non-randomised control trial with a questionnaire survey.

Morikawa M, Yamada T, Kogo H, Sugawara M, Nishikawa A, Fukushi Y, Hirayama EK, Ishioka SI, Watari H.

BMJ Open. 2019 Sep 20;9(9):e031839. doi: 10.1136/bmjopen-2019-031839.

5.

Ovarian primary and metastatic tumors suppressed by survivin knockout or a novel survivin inhibitor.

Zhao G, Wang Q, Wu Z, Tian X, Yan H, Wang B, Dong P, Watari H, Pfeffer LM, Guo Y, Li W, Yue J.

Mol Cancer Ther. 2019 Sep 12. pii: molcanther.0118.2019. doi: 10.1158/1535-7163.MCT-19-0118. [Epub ahead of print]

PMID:
31515295
6.

Antimicrobial susceptibility surveillance of obligate anaerobic bacteria in the Kinki area.

Shimura S, Watari H, Komatsu M, Kuchibiro T, Fukuda S, Nishio H, Kita M, Kida K, Oohama M, Toda H, Nishio M, Nishi I, Kimura K, Sawa K, Fukuda N, Kofuku T, Nakai I, Niki M, Ono T, Nakamura T, Wada Y.

J Infect Chemother. 2019 Nov;25(11):837-844. doi: 10.1016/j.jiac.2019.07.018. Epub 2019 Aug 17.

PMID:
31427200
7.

MicroRNA-361: A Multifaceted Player Regulating Tumor Aggressiveness and Tumor Microenvironment Formation.

Xu D, Dong P, Xiong Y, Yue J, Ihira K, Konno Y, Kobayashi N, Todo Y, Watari H.

Cancers (Basel). 2019 Aug 7;11(8). pii: E1130. doi: 10.3390/cancers11081130. Review.

8.

Long noncoding RNA NEAT1 drives aggressive endometrial cancer progression via miR-361-regulated networks involving STAT3 and tumor microenvironment-related genes.

Dong P, Xiong Y, Yue J, Xu D, Ihira K, Konno Y, Kobayashi N, Todo Y, Watari H.

J Exp Clin Cancer Res. 2019 Jul 8;38(1):295. doi: 10.1186/s13046-019-1306-9.

9.

Kihito, a Traditional Japanese Kampo Medicine, Improves Cognitive Function in Alzheimer's Disease Patients.

Watari H, Shimada Y, Matsui M, Tohda C.

Evid Based Complement Alternat Med. 2019 May 14;2019:4086749. doi: 10.1155/2019/4086749. eCollection 2019.

10.

Adverse Events Associated with Ethical Kampo Formulations: Analysis of the Domestic Adverse-Event Data Reports of the Ministry of Health, Labor, and Welfare in Japan.

Shimada Y, Fujimoto M, Nogami T, Watari H.

Evid Based Complement Alternat Med. 2019 Apr 15;2019:1643804. doi: 10.1155/2019/1643804. eCollection 2019.

11.

A novel sponge-derived protein thrombocorticin is a new agonist for thrombopoietin receptor.

Watari H, Nakajima H, Atsuumi W, Nakamura T, Nanya T, Ise Y, Sakai R.

Comp Biochem Physiol C Toxicol Pharmacol. 2019 Jul;221:82-88. doi: 10.1016/j.cbpc.2019.04.003. Epub 2019 Apr 9.

PMID:
30978513
12.

Maternal Anemia and Coagulation/Fibrinolysis after Fetoscopic Laser Photocoagulation for Twin-to-Twin Transfusion Syndrome.

Morikawa M, Yamada T, Nakagawa K, Hosokawa-Miyanishi A, Umazume T, Chiba K, Kawaguchi S, Cho K, Watari H.

Gynecol Obstet Invest. 2019;84(5):477-484. doi: 10.1159/000499913. Epub 2019 Apr 9.

PMID:
30965339
13.

Increase in the number of patients diagnosed using the new classification of hypertensive disorders of pregnancy in Japan.

Mayama M, Morikawa M, Umazume T, Nakagawa K, Hosokawa A, Yamaguchi M, Chiba K, Kawaguchi S, Watari H.

J Obstet Gynaecol Res. 2019 Jun;45(6):1118-1126. doi: 10.1111/jog.13955. Epub 2019 Mar 28.

PMID:
30924214
14.

Exploring lncRNA-Mediated Regulatory Networks in Endometrial Cancer Cells and the Tumor Microenvironment: Advances and Challenges.

Dong P, Xiong Y, Yue J, J B Hanley S, Kobayashi N, Todo Y, Watari H.

Cancers (Basel). 2019 Feb 16;11(2). pii: E234. doi: 10.3390/cancers11020234. Review.

15.

Asian Society of Gynecologic Oncology International Workshop 2018.

Kong TW, Ryu HS, Kim SC, Enomoto T, Li J, Kim KH, Shim SH, Wang PH, Therasakvichya S, Kobayashi Y, Lee M, Shi T, Lee SW, Mikami M, Nagase S, Lim MC, Wang J, Wilailak S, Kim SW, Hong SH, Tan DS, Mandai M, Chang SJ, Huang RYJ, Ushijima K, Lee JY, Chen X, Ochiai K, Lee TS, Yang B, Kalam F, Lv Q, Ahmad MF, Yaznil MR, Modi KB, Manopunya M, Jeong DH, Lertkhachonsuk AA, Chung HH, Watari H, Jeon S.

J Gynecol Oncol. 2019 Mar;30(2):e39. doi: 10.3802/jgo.2019.30.e39. Epub 2019 Jan 14.

16.

Relationship between antithrombin activity and interval from diagnosis to delivery among pregnant women with early-onset pre-eclampsia.

Morikawa M, Umazume T, Hosokawa-Miyanishi A, Watari H, Kobayashi T, Seki H, Saito S.

Int J Gynaecol Obstet. 2019 Apr;145(1):62-69. doi: 10.1002/ijgo.12780. Epub 2019 Feb 21.

PMID:
30714139
17.

Correction: Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.

Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S, Hanley SJB, Yue J, Watari H, Sakuragi N.

Oncogene. 2019 May;38(20):3972. doi: 10.1038/s41388-019-0677-x.

PMID:
30679789
18.

Knockout of MTF1 Inhibits the Epithelial to Mesenchymal Transition in Ovarian Cancer Cells.

Ji L, Zhao G, Zhang P, Huo W, Dong P, Watari H, Jia L, Pfeffer LM, Yue J, Zheng J.

J Cancer. 2018 Nov 11;9(24):4578-4585. doi: 10.7150/jca.28040. eCollection 2018.

19.

Molecular-targeted therapies and precision medicine for endometrial cancer.

Mitamura T, Dong P, Ihira K, Kudo M, Watari H.

Jpn J Clin Oncol. 2019 Feb 1;49(2):108-120. doi: 10.1093/jjco/hyy159. Review.

PMID:
30423148
20.

Long Non-coding RNA NEAT1: A Novel Target for Diagnosis and Therapy in Human Tumors.

Dong P, Xiong Y, Yue J, Hanley SJB, Kobayashi N, Todo Y, Watari H.

Front Genet. 2018 Oct 15;9:471. doi: 10.3389/fgene.2018.00471. eCollection 2018. Review.

21.

Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion.

Dong P, Xiong Y, Yue J, Hanley SJB, Watari H.

Front Oncol. 2018 Sep 19;8:386. doi: 10.3389/fonc.2018.00386. eCollection 2018. Review.

22.

miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathway.

Wang B, Li X, Zhao G, Yan H, Dong P, Watari H, Sims M, Li W, Pfeffer LM, Guo Y, Yue J.

J Exp Clin Cancer Res. 2018 Sep 21;37(1):235. doi: 10.1186/s13046-018-0906-0.

23.

Metformin reverses early cortical network dysfunction and behavior changes in Huntington's disease.

Arnoux I, Willam M, Griesche N, Krummeich J, Watari H, Offermann N, Weber S, Narayan Dey P, Chen C, Monteiro O, Buettner S, Meyer K, Bano D, Radyushkin K, Langston R, Lambert JJ, Wanker E, Methner A, Krauss S, Schweiger S, Stroh A.

Elife. 2018 Sep 4;7. pii: e38744. doi: 10.7554/eLife.38744.

24.

miR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2.

Mohamed Z, Hassan MK, Okasha S, Mitamura T, Keshk S, Konno Y, Kato T, El-Khamisy SF, Ohba Y, Watari H.

Oncotarget. 2018 Jul 10;9(53):30053-30065. doi: 10.18632/oncotarget.25698. eCollection 2018 Jul 10.

25.

B7H3 As a Promoter of Metastasis and Promising Therapeutic Target.

Dong P, Xiong Y, Yue J, Hanley SJB, Watari H.

Front Oncol. 2018 Jul 6;8:264. doi: 10.3389/fonc.2018.00264. eCollection 2018. Review.

26.

Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.

Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S, Hanley SJB, Yue J, Watari H, Sakuragi N.

Oncogene. 2018 Sep;37(39):5257-5268. doi: 10.1038/s41388-018-0347-4. Epub 2018 May 31. Erratum in: Oncogene. 2019 Jan 24;:.

27.

miR-34a, miR-424 and miR-513 inhibit MMSET expression to repress endometrial cancer cell invasion and sphere formation.

Dong P, Xiong Y, Yue J, Hanley SJB, Watari H.

Oncotarget. 2018 May 1;9(33):23253-23263. doi: 10.18632/oncotarget.25298. eCollection 2018 May 1.

28.

Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.

Aoyama-Kikawa S, Fujita H, Hanley SJB, Kasamo M, Kikuchi K, Torigoe T, Matsuno Y, Tamakoshi A, Sasaki T, Matsuura M, Kato Y, Dong P, Watari H, Saito T, Sengoku K, Sakuragi N.

Cancer Sci. 2018 Jun;109(6):2003-2012. doi: 10.1111/cas.13608. Epub 2018 May 31.

29.

Lentiviral vector mediated-ASAP1 expression promotes epithelial to mesenchymal transition in ovarian cancer cells.

Zhang T, Zhao G, Yang C, Dong P, Watari H, Zeng L, Pfeffer LM, Yue J.

Oncol Lett. 2018 Apr;15(4):4432-4438. doi: 10.3892/ol.2018.7834. Epub 2018 Jan 22.

30.

Recurrent Drug-induced Liver Injury Caused by the Incidental Readministration of a Kampo Formula Containing Scutellariae Radix.

Shimada Y, Fujimoto M, Nogami T, Watari H, Kitahara H, Misawa H, Kimbara Y, Kita KI.

Intern Med. 2018 Jun 15;57(12):1733-1740. doi: 10.2169/internalmedicine.0275-17. Epub 2018 Feb 9.

31.

Patient safety incident reports related to traditional Japanese Kampo medicines: medication errors and adverse drug events in a university hospital for a ten-year period.

Shimada Y, Fujimoto M, Nogami T, Watari H, Kitahara H, Misawa H, Kimbara Y.

BMC Complement Altern Med. 2017 Dec 21;17(1):547. doi: 10.1186/s12906-017-2051-2.

32.

Evaluation of the modified carbapenem inactivation method for the detection of carbapenemase-producing Enterobacteriaceae.

Kuchibiro T, Komatsu M, Yamasaki K, Nakamura T, Nishio H, Nishi I, Kimura K, Niki M, Ono T, Sueyoshi N, Kita M, Kida K, Ohama M, Satoh K, Toda H, Mizutani T, Fukuda N, Sawa K, Nakai I, Kofuku T, Orita T, Watari H, Shimura S, Fukuda S, Nakamura A, Wada Y.

J Infect Chemother. 2018 Apr;24(4):262-266. doi: 10.1016/j.jiac.2017.11.010. Epub 2017 Dec 14.

PMID:
29248418
33.

Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells.

Zhao G, Wang Q, Gu Q, Qiang W, Wei JJ, Dong P, Watari H, Li W, Yue J.

Oncotarget. 2017 Oct 17;8(55):94666-94680. doi: 10.18632/oncotarget.21863. eCollection 2017 Nov 7.

34.

Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation.

Dong P, Xiong Y, Hanley SJB, Yue J, Watari H.

J Exp Clin Cancer Res. 2017 Oct 26;36(1):150. doi: 10.1186/s13046-017-0617-y.

35.

Diosgenin-Rich Yam Extract Enhances Cognitive Function: A Placebo-Controlled, Randomized, Double-Blind, Crossover Study of Healthy Adults.

Tohda C, Yang X, Matsui M, Inada Y, Kadomoto E, Nakada S, Watari H, Shibahara N.

Nutrients. 2017 Oct 24;9(10). pii: E1160. doi: 10.3390/nu9101160.

36.

The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma In Vitro and In Vivo.

Nakatani M, Watari H, Mitamura T, Wang L, Hatanaka Y, Hatanaka KC, Honda K, Nomura T, Nishihara H, Tanaka S, Sakuragi N.

Anticancer Res. 2017 Nov;37(11):6125-6132.

PMID:
29061793
37.

Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer: Japan Clinical Oncology Group Study 1412 (SEPAL-P3).

Watari H, Katayama H, Shibata T, Ushijima K, Satoh T, Onda T, Aoki D, Fukuda H, Yaegashi N, Sakuragi N; Gynecologic Cancer Study Group of the Japan Clinical Oncology Group.

Jpn J Clin Oncol. 2017 Oct 1;47(10):986-990. doi: 10.1093/jjco/hyx108.

PMID:
28981739
38.

Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.

Itamochi H, Oishi T, Oumi N, Takeuchi S, Yoshihara K, Mikami M, Yaegashi N, Terao Y, Takehara K, Ushijima K, Watari H, Aoki D, Kimura T, Nakamura T, Yokoyama Y, Kigawa J, Sugiyama T.

Br J Cancer. 2017 Aug 22;117(5):717-724. doi: 10.1038/bjc.2017.228. Epub 2017 Jul 20.

39.

Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02).

Ohnishi S, Watari H, Kanno M, Ohba Y, Takeuchi S, Miyaji T, Oyamada S, Nomura E, Kato H, Sugiyama T, Asaka M, Sakuragi N, Yamaguchi T, Uezono Y, Iwase S.

J Gynecol Oncol. 2017 Sep;28(5):e44. doi: 10.3802/jgo.2017.28.e44. Epub 2017 Mar 17.

40.

iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling.

Xiong Y, Sun F, Dong P, Watari H, Yue J, Yu MF, Lan CY, Wang Y, Ma ZB.

J Exp Clin Cancer Res. 2017 Apr 11;36(1):48. doi: 10.1186/s13046-017-0520-6.

41.

Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells.

Huo W, Zhao G, Yin J, Ouyang X, Wang Y, Yang C, Wang B, Dong P, Wang Z, Watari H, Chaum E, Pfeffer LM, Yue J.

J Cancer. 2017 Jan 1;8(1):57-64. doi: 10.7150/jca.16723. eCollection 2017.

42.

KLF4 expression enhances the efficacy of chemotherapy drugs in ovarian cancer cells.

Wang B, Shen A, Ouyang X, Zhao G, Du Z, Huo W, Zhang T, Wang Y, Yang C, Dong P, Watari H, Pfeffer LM, Yue J.

Biochem Biophys Res Commun. 2017 Mar 11;484(3):486-492. doi: 10.1016/j.bbrc.2017.01.062. Epub 2017 Jan 18.

PMID:
28108288
43.

EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis.

Ihira K, Dong P, Xiong Y, Watari H, Konno Y, Hanley SJ, Noguchi M, Hirata N, Suizu F, Yamada T, Kudo M, Sakuragi N.

Oncotarget. 2017 Feb 21;8(8):13509-13520. doi: 10.18632/oncotarget.14586.

44.

Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group study.

Kang S, Nam JH, Bae DS, Kim JW, Kim MH, Chen X, No JH, Lee JM, Kim JH, Watari H, Kim SM, Kim SH, Seong SJ, Kim KT, Kim SC, Kim JH, Lim MC, Lee JY, Ryu SY, Yang B, Kim BG.

Cancer. 2017 Jan 1;123(2):263-272. doi: 10.1002/cncr.30349. Epub 2016 Nov 7.

45.

Suppression of iASPP-dependent aggressiveness in cervical cancer through reversal of methylation silencing of microRNA-124.

Dong P, Xiong Y, Watari H, Hanley SJ, Konno Y, Ihira K, Suzuki F, Yamada T, Kudo M, Yue J, Sakuragi N.

Sci Rep. 2016 Oct 21;6:35480. doi: 10.1038/srep35480.

46.

MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells.

Dong P, Xiong Y, Watari H, Hanley SJ, Konno Y, Ihira K, Yamada T, Kudo M, Yue J, Sakuragi N.

J Exp Clin Cancer Res. 2016 Sep 5;35(1):132. doi: 10.1186/s13046-016-0415-y.

47.

Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells.

Baghdadi M, Wada H, Nakanishi S, Abe H, Han N, Putra WE, Endo D, Watari H, Sakuragi N, Hida Y, Kaga K, Miyagi Y, Yokose T, Takano A, Daigo Y, Seino KI.

Cancer Res. 2016 Oct 15;76(20):6030-6042. Epub 2016 Aug 22.

48.

[The annual changes in antimicrobial susceptibility test results of Pseudomonas aeruginosa isolates from the Kinki district].

Fukuda S, Komatsu M, Nakamura T, Jikimoto T, Nishio H, Yamasaki K, Satoh K, Toda H, Orita T, Sueyoshi N, Kita M, Nishi I, Akagi M, Higuchi T, Kofuku T, Nakai I, Ono T, Kida K, Ohama M, Watari H, Shimura S, Niki M, Kuchibiro T, Wada Y.

Jpn J Antibiot. 2016 Apr;69(2):101-10. Japanese.

PMID:
27544978
49.

Chemotherapy and molecular targeting therapy for recurrent cervical cancer.

Tsuda N, Watari H, Ushijima K.

Chin J Cancer Res. 2016 Apr;28(2):241-53. doi: 10.21147/j.issn.1000-9604.2016.02.14.

50.

Neoadjuvant chemotherapy for locally advanced cervical cancer.

Iwata T, Miyauchi A, Suga Y, Nishio H, Nakamura M, Ohno A, Hirao N, Morisada T, Tanaka K, Ueyama H, Watari H, Aoki D.

Chin J Cancer Res. 2016 Apr;28(2):235-40. doi: 10.21147/j.issn.1000-9604.2016.02.13.

Supplemental Content

Loading ...
Support Center